Guardant360® Liquid
Comprehensive liquid biopsy for advanced solid tumour treatment guidance
The first and only commercially available liquid biopsy to deliver genomic and epigenomic insights from a single input for the most complete view of cancer. Guardant360 Liquid is guideline-complete across all advanced solid tumors,and includes TMB, MSI status, tumor fraction, and ever-expanding epigenomic features. Guardant360 Liquid taps into 19,000+ epigenomic signals through ever-expanding test features, enabling more precise treatment choices and response prediction.
Oncologists managing patients with advanced solid tumours who need comprehensive genomic profiling to guide targeted therapy selection or identify clinical trial eligibility.
- Hematologic malignancies
- Early stage (stage I/II) cancers
- When disease is stable or responding to therapy
740+ gene panel, MSI-High status, TMB, promoter methlyation, Molecular tumour typing, Lung/Breast subtyping, Pharmacogenomics (CYP2D6, DPYD, TPMT, UGT1A1, HLA allele HLA-B *58:01)
| Step / Test | Accuracy | Notes |
|---|---|---|
| Sensitivity | 95% | |
| Specificity | 99.9% |
2 × 10ml Streck Cell-Free DNA BCT® tubes
20 mL peripheral blood collected into 2 × Streck Cell-Free DNA BCT® tubes. Collected by a licensed healthcare professional.
Collection, packaging, and shipping must follow the Guardant 360 Blood Collection Kit (BCK) Instructions for Use, including tube type and transport requirements.
Guardant360® is available through Codex Genetics as the authorised distributor in Hong Kong. Please contact us for ordering, sample collection kits, and shipping instructions.
Samples must be collected and submitted through an authorised healthcare provider.
- Collect blood into Streck Cell-Free DNA BCT® tubes (room-temperature stable up to 14 days).
- Do NOT centrifuge. Ship tubes intact at ambient temperature; avoid freezing or >37°C.
- Include completed test requisition form. Address: Unit 220, 2/F, Building 16W, HKSTP, Pak Shek Kok, NT, Hong Kong.
Please refer to the technical documentation: https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Report-Interpretation.pdf
Guardant360® CGP detects somatic variants in 740+ gene panel, MSI-High status, TMB, promoter methlyation, Molecular Tumor Typing, Lung/Breast subtyping, and pharmacogenomics.
Hong Kong-based molecular diagnostics laboratory specialising in clinical genomics, precision oncology, and rare disease diagnosis. Accredited to ISO 27001 and GenQA standards.
© 2026 Codex Genetics Limited. All rights reserved.
